AUY922, a novel HSP90 inhibitor: Final results of a First-in-human study in patients with advanced solid malignancies.

被引：23
|
作者：
Samuel, T. A.
Sessa, C.
Britten, C.
Milligan, K. S.
Mita, M. M.
Banerji, U.
Pluard, T. J.
Stiegler, P.
Quad, C.
Shapiro, G.
机构：
[1] Med Coll Georgia, Augusta, GA 30912 USA
[2] Osped Reg Bellinzona & Valli, Oncol Inst Southern Switzerland, Bellinzona, Switzerland
[3] Univ Calif Los Angeles, Clin Res Unit, Los Angeles, CA USA
[4] Nevada Canc Inst, Las Vegas, NV USA
[5] Canc Therapy & Res Ctr S Texas, San Antonio, TX 78229 USA
[6] Royal Marsden Hosp, Drug Dev Unit, Sutton, Surrey, England
[7] Washington Univ, Sch Med, Div Med Oncol, St Louis, MO USA
[8] Novartis Pharmaceut, E Hanover, NJ USA
[9] Novartis Pharmaceut, Basel, Switzerland
[10] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.2528
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2528
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase I dose escalation study of AUY922, a novel HSP90 inhibitor, in patients with advanced solid malignancies
    Sessa, C.
    Sharma, S. K.
    Britten, C. D.
    Vogelzang, N. J.
    Bhalla, K. N.
    Mita, M. M.
    Pluard, T. J.
    Stiegler, P.
    Quadt, C.
    Shapiro, G. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors
    Sessa, Cristiana
    Shapiro, Geoffrey I.
    Bhalla, Kapil N.
    Britten, Carolyn
    Jacks, Karen S.
    Mita, Monica
    Papadimitrakopoulou, Vali
    Pluard, Tim
    Samuel, Thomas A.
    Akimov, Mikhail
    Quadt, Cornelia
    Fernandez-Ibarra, Cristina
    Lu, Hong
    Bailey, Stuart
    Chica, Sandra
    Banerji, Udai
    CLINICAL CANCER RESEARCH, 2013, 19 (13) : 3671 - 3680
  • [3] Preclinical Study of AUY922, a Novel Hsp90 Inhibitor, in the Treatment of Esophageal Adenocarcinoma
    Kosovec, Juliann E.
    Zaidi, Ali H.
    Kelly, Lori A.
    Rotoloni, Christina L.
    Vytlacil, Christopher
    DiCarlo, Christina
    Matsui, Daisuke
    Komatsu, Yoshihiro
    Boyd, Natalie H.
    Omstead, Ashten
    Kolano, Elena L.
    Biederman, Robert W. W.
    Finley, Gene
    Silverman, Jan F.
    Landreneau, Rodney J.
    Jobe, Blair A.
    ANNALS OF SURGERY, 2016, 264 (02) : 297 - 304
  • [4] A Phase I Study of the Hsp90 Inhibitor AUY922 plus Capecitabine for the Treatment of Patients with Advanced Solid Tumors
    Bendell, Johanna C.
    Jones, Suzanne F.
    Hart, Lowell
    Pant, Shubham
    Moyhuddin, Adil
    Lane, Cassie M.
    Earwood, Chris
    Murphy, Patrick
    Patton, Jeffrey
    Penley, William C.
    Thompson, Dana
    Infante, Jeffrey R.
    CANCER INVESTIGATION, 2015, 33 (10) : 477 - 482
  • [5] Phase I study of the HSP90 inhibitor AUY922 in combination with capecitabine as treatment for patients with advanced solid tumors
    Pant, Shubham
    Hart, Lowell L.
    Bendell, Johanna C.
    Infante, Jeffrey R.
    Jones, Suzanne Fields
    Mohyuddin, Adil
    Murphy, Patrick
    Patton, Jeffrey
    Penley, William Charles
    Thompson, Dana Shelton
    Burris, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Phase I study of the HSP90 inhibitor AUY922 in combination with capecitabine as treatment for patients with advanced solid tumors
    Bendell, Johanna C.
    Hart, Lowell L.
    Pant, Shubham
    Infante, Jeffrey R.
    Jones, Suzanne Fields
    Mohyuddin, Adil
    Murphy, Patrick
    Patton, Jeffrey
    Penley, William Charles
    Thompson, Dana Shelton
    Burris, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [7] Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors
    Toshihiko Doi
    Yusuke Onozawa
    Nozomu Fuse
    Takayuki Yoshino
    Kentaro Yamazaki
    Junichiro Watanabe
    Mikhail Akimov
    Matthew Robson
    Narikazu Boku
    Atsushi Ohtsu
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 629 - 636
  • [8] Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors
    Doi, Toshihiko
    Onozawa, Yusuke
    Fuse, Nozomu
    Yoshino, Takayuki
    Yamazaki, Kentaro
    Watanabe, Junichiro
    Akimov, Mikhail
    Robson, Matthew
    Boku, Narikazu
    Ohtsu, Atsushi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (03) : 629 - 636
  • [9] Role of the novel HSP90 inhibitor AUY922 in hepatocellular carcinoma: Potential for therapy
    Cheng, Wei
    Ainiwaer, Aimudula
    Xiao, Lei
    Cao, Qian
    Wu, Ge
    Yang, Ying
    Mao, Rui
    Bao, Yongxing
    MOLECULAR MEDICINE REPORTS, 2015, 12 (02) : 2451 - 2456
  • [10] A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer
    D. J. Renouf
    D. Hedley
    M. K. Krzyzanowska
    M. Schmuck
    L. Wang
    M. J. Moore
    Cancer Chemotherapy and Pharmacology, 2016, 78 : 541 - 545
12345